Revolutionary trial outcomes broaden the range of treatment alternatives for individuals grappling with bladder cancer.
Drugs Approved for Bladder Cancer
Adstiladrin (Nadofaragene Firadenovec-vncg)
Avelumab
Balversa (Erdafitinib)
Bavencio (Avelumab)
Cisplatin
Doxorubicin Hydrochloride
Enfortumab Vedotin-ejfv
Erdafitinib
Jelmyto (Mitomycin)
Keytruda (Pembrolizumab)
Mitomycin
Nadofaragene Firadenovec-vncg
Nivolumab
Opdivo (Nivolumab)
Padcev (Enfortumab Vedotin-ejfv)
Pemazyre (Pemigatinib)
Pembrolizumab
Pemigatinib
Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder Cancer
UPDATE: As of December 15, 2023, the Food and Drug Administration (FDA) has granted approval to enfortumab vedotin (Padcev) in conjunction with pembrolizumab (Keytruda) for individuals with bladder cancer that has metastasized or is non-surgically removable.This approval stems from the outcomes of the EV-302 trial, revealing that the enfortumab-pembrolizumab combination doubled the survival duration for individuals with advanced bladder cancer in comparison to those treated with conventional chemotherapy. Further details on the trial results are discussed in the subsequent story.
The outlook for bladder cancer is influenced by various factors, including
The cancer stage, distinguishing between non-muscle-invasive (superficial) bladder cancer and muscle-invasive (invasive) bladder cancer, which extends beyond the bladder’s muscle wall.
The specific type of bladder cancer.
The tumor’s grade, categorizing it as either low grade or high grade.
The patient’s age and overall health.
In cases of non-muscle-invasive bladder cancer, the outlook is influenced by additional factors such as:
The presence of many tumors or large tumors.
Whether the cancer has extended into the connective tissue adjacent to the bladder lining.
The recurrence of cancer after treatment
Non-muscle-invasive bladder cancer frequently has a favorable prognosis and is often curable.
Is medication a viable treatment for bladder cancer?
Chemotherapy employs drugs to eliminate cancer cells, typically using a combination of two or more chemotherapy drugs. The administration of chemotherapy drugs can occur intravenously, delivering them through a vein.
show less